RET
Read More about this categoryShow Less
RET (REarranged during Transfection) is a receptor protein tyrosine kinase, which activates multiple signal transduction pathways. RET protein is composed of three domains: an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic tyrosine kinase domain. The RET receptor tyrosine kinase (RTK) regulates key aspects of cellular proliferation and survival by regulating the activity of the mitogen- activated protein kinase (MAPK) and PI3K/Akt signaling pathways. RET also interacts directly with other kinases such as the epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) and the focal adhesion kinase (FAK). Furthermore, BRAF and p38MAPK are downstream targets of RET. Kinase inhibitors that simultaneously inhibit RET and its downstream targets.
RET tyrosine kinase receptor presents an attractive therapeutic target for the treatment of certain cancer subsets. Deregulated RET activity has been identified as a causative factor in the development, progression and response to therapy of thyroid carcinoma. Elevated RET expression has been associated with the development of endocrine resistance in human breast cancer.
Products Related to RET(32)
- GC65354EnbezotinibCAS: 2359649-81-1Purity: >99.00%
RET 억제제인 엔베조티닙은 RET 자가인산화를 억제할 수 있습니다. 엔베조티닙은 암 연구에 사용될 수 있습니다.
- GC81325VEGFR2-IN-84CAS: 861877-12-5Purity: >98%
VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC65354 | Enbezotinib | 2359649-81-1 | >99.00% | |
RET 억제제인 엔베조티닙은 RET 자가인산화를 억제할 수 있습니다. 엔베조티닙은 암 연구에 사용될 수 있습니다. | ||||
| GC67917 | RET-IN-7 | 2763386-05-4 | >98% | |
| GC68396 | Vepafestinib | 2129515-96-2 | >98.00% | |
| GC68623 | AD57 | 1093380-42-7 | >98.00% | |
AD57는 경구 효능을 가진 다중 키나제 억제제로, RET, BRAF, S6K 및 Src 활성을 억제하지만 mTOR의 활성은 뚜렷하게 감소합니다. | ||||
| GC68812 | BT44 | 924759-42-2 | >99.00% | |
BT44는 선택적인 RET 활성제입니다. BT44는 혈-뇌 장벽을 통과하여 신경퇴화성 질환 및 당뇨병 연구에 사용될 수 있습니다. | ||||
| GC73196 | RET-IN-21 | 2414373-42-3 | >97.00% | |
RET-IN-21은 수용체의 억제-dopa 산화효소 (RET), 4. 4 μ M의 IC50으로, 그것은 antitumor 활동이다. | ||||
| GC79484 | APS03118 | 2598870-24-5 | >98.50% | |
APS03118 is an orally active, potent and selective rearranged during transfection ( RET ) inhibitor. | ||||
| GC81325 | VEGFR2-IN-84 | 861877-12-5 | >98% | |
VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold. | ||||
